Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-15
DOI
10.1111/cas.14306
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The potentials of CCL 2‐ CCR 2 blockers including propagermanium as anticancer agents
- (2019) Kanae Yumimoto et al. CANCER SCIENCE
- Interactions in the (Pre)metastatic Niche Support Metastasis Formation
- (2019) Ginevra Doglioni et al. Frontiers in Oncology
- PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
- (2018) Zhong Lei et al. Cell Death & Disease
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Paget’s “Seed and Soil” Theory of Cancer Metastasis
- (2018) Mohammed Akhtar et al. ADVANCES IN ANATOMIC PATHOLOGY
- High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer
- (2018) Marja Heiskala et al. VIRCHOWS ARCHIV
- Targeting the CCL2-CCR2 signaling axis in cancer metastasis
- (2016) Su Yin Lim et al. Oncotarget
- Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project
- (2015) Megumi Hori et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner
- (2015) Kanae Yumimoto et al. JOURNAL OF CLINICAL INVESTIGATION
- Fbxw7 suppresses cancer metastasis by inhibiting niche formation
- (2015) Kanae Yumimoto et al. OncoImmunology
- Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
- (2014) Laura Bonapace et al. NATURE
- A New Approach to Reducing Postsurgical Cancer Recurrence: Perioperative Targeting of Catecholamines and Prostaglandins
- (2012) E. Neeman et al. CLINICAL CANCER RESEARCH
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression
- (2009) Hiroshi Fujimoto et al. INTERNATIONAL JOURNAL OF CANCER
- Chemokine (C-C Motif) Ligand 2 Engages CCR2+Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone
- (2009) Xin Lu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now